

Supporting Information

Li et al. 10.1073/pnas.1424171112




Fig. S1. Body weight observation after gemcitabine or BB608 treatment. (A) Immunosuppressed mice with established s.c. Paca-2 human pancreatic cancer were given gemcitabine (120 mg/kg), or vehicle control i.p. All regimens were administered q3d. Body weight was measured periodically during the treatment. There were no significant changes in body weight due to administration of the vehicle, or with administration of gemcitabine. (B) Immunosuppressed mice with established s.c. Paca-2 human pancreatic cancer were given BB608 (20 mg/kg), or vehicle control i.p. All regimens were administered daily. Body weight was measured periodically during the treatment. There were no significant changes in body weight due to administration of the vehicle, or with administration of BB608.